Program
penpulimab
Also written as “AK105”, “Penpulimab” and “Penpulimab injection”.
Its studies are mostly in Carcinoma, Hepatocellular · Nasopharyngeal Carcinoma · Carcinoma, Non-Small-Cell Lung · Hodgkin Disease · Esophageal Squamous Cell Carcinoma, led by 2 companies.
Drug pagePenpulimab: every studyAll 65 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Sino Biopharmaceuticalits history only | 187 open or running | phase 3since Apr 10, 2020 | Dec 17, 2019 | Dec 2026phase 3 · NCT04344158 |
| Akeso | 92 open or running | phase 3since Mar 6, 2019 | Nov 21, 2017 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Akeso only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
- Nov 21, 2017First study: phase 1 study in Advanced CancerFirst studyNCT03352531 · 99 enrolled · Australia
- Oct 25, 2018Phase 2 study in Hodgkin DiseaseNCT03722147 · 94 enrolled · China
- Mar 6, 20192 phase 3 studies in Carcinoma, Non-Small-Cell LungNCT03866993, NCT03866980
- Mar 6, 2019Phase 2 study in Nasopharyngeal CarcinomaNCT03866967 · 130 enrolled · China
- Nov 19, 20192 phase 2 studiesNCT04172571, NCT04172506
- Jun 9, 2020Named penpulimabINNProposed as its International Nonproprietary Name in WHO's List 123 · before, AK105
- Jul 13, 2021Phase 3 study in Nasopharyngeal CarcinomaNCT04974398 · 296 enrolled · United States, Australia, Brazil and more
- Jan 25, 2022Phase 3 study in Hodgkin Disease LymphomaNCT05244642 · 60 planned · China
TargetBeta
“A monoclonal antibody directed against the negative immunoregulatory human cell receptor programmed cell death protein 1 (PD-1; PDCD1; CD279), ”NCIt, by rule
“Programmed cell death protein 1 inhibitor”ChEMBL 37, by rule
Other programs on PDCD1
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| ivonescimabrule | Akeso | phase 3 | 48 |
| rilvegostomig | AstraZeneca | phase 3 | 24 |
| Iparomlimab/Tuvonralimabrule | Qilu Pharmaceutical | phase 3 | 22 |
| volrustomig | AstraZeneca | phase 3 | 19 |
| tivunatamig | Pfizer | phase 3 | 15 |
| nilvanstomigrule | Suzhou Zelgen Biopharmaceuticals | phase 3 | 15 |
| pucotenlimabrule | taizhou-hanzhong-biomedical-co-ltd | phase 3 | 15 |
| enlonstobartrule | CSPC Pharmaceutical Group | phase 3 | 15 |
| ezabenlimab | Boehringer Ingelheim | phase 3 | 13 |
| Anti-PD-1/IL-2 Bispecific Antibody Fusion Protein IBI363rule | Innovent Biologics | phase 3 | 10 |
| rulonilimabrule | Lunan Pharmaceutical Group | phase 3 | 9 |
| Anti-PD-1/Anti-TGF-beta Bifunctional Fusion Protein TQB2868 | Sino Biopharmaceutical | phase 3 | 4 |
Studies
All 9 Akeso leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT05244642Hodgkin Disease Lymphoma · China | 3 | Recruiting | Dec 30, 2025 | 60 |
| NCT04974398Nasopharyngeal Carcinoma · United States, Australia, Brazil and more | 3 | Active, not recruiting | Feb 23, 2026 | 296 |
| NCT04172571Carcinoma, Hepatocellular · China | 2 | Completed | Jun 1, 2022 | 31 |
| NCT04172506Lung Neoplasms · China | 2 | Completed | Dec 1, 2021 | 65 |
| NCT03866993Carcinoma, Non-Small-Cell Lung · China | 3 | Completed | Oct 8, 2020 | 350 |
| NCT03866980Carcinoma, Non-Small-Cell Lung · China | 3 | Terminated | Jun 30, 2023 | 164 |
| NCT03866967Nasopharyngeal Carcinoma · China | 2 | Completed | Mar 13, 2021 | 130 |
| NCT03722147Hodgkin Disease · China | 2 | Completed | Jan 10, 2020 | 94 |
| NCT03352531Advanced Cancer · Australia | 1 | Completed | Nov 30, 2020 | 99 |
How it is read
Names in the registry
- “AK105”, 9 entries
- “Penpulimab”, 3 entries
- “Penpulimab injection”, 2 entries
- “AK105 injection”, 2 entries
- “TQB2618 injection; Penpulimab injection”, 1 entry
Conditions, from the studies’ own filings
- Carcinoma, Hepatocellular, 5 studies
- Nasopharyngeal Carcinoma, 3 studies
- Carcinoma, Non-Small-Cell Lung, 2 studies
- Hodgkin Disease, 2 studies
- Esophageal Squamous Cell Carcinoma, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.